ADMA 10-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– HBSS

A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly misrepresenting its financial condition, engaging in channel stuffing, undisclosed related-party transactions, and lacking adequate internal controls. The allegations were exposed by a Culper Research short-seller report on March 24, 2026, causing the stock to plunge 31.6% over two trading days. Investors with substantial losses are urged to contact Hagens Berman by the August 10, 2026 deadline to participate in the class action.